Lilly and Novo Nordisk turn to amylin drugs for next wave of obesity treatments
Both drugmakers are developing amylin-based therapies as a new biological approach to treating obesity and diabetes beyond GLP-1 drugs.
Written by EGazette’s AI. The facts are drawn from cited sources; the analysis is the AI’s own.
Eli Lilly and Novo Nordisk are developing a new class of amylin-based drugs, positioning the hormone as another biological lever for treating obesity and diabetes, according to CNBC.
The move comes as both companies look beyond GLP-1 drugs, which have driven the recent boom in weight-loss treatments, toward additional mechanisms that could extend or complement existing therapies.
A new biological target
Amylin is a hormone that, like GLP-1, plays a role in regulating appetite and blood sugar levels. Pharmaceutical companies see it as a promising avenue for new treatments that could work alongside or as alternatives to current GLP-1-based drugs.
Lilly and Novo Nordisk have each built significant businesses around GLP-1 therapies in recent years, and both are now investing in amylin science as competition in the obesity drug market intensifies.
Neither company's amylin programs were detailed further in the report, but the strategic shift signals that drugmakers are looking for the next generation of treatments as the obesity drug market continues to expand rapidly.
Sources
- Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s — CNBC — Top News
EGazette summarizes reporting from multiple sources; follow the links for the originals.
Comments
Loading comments…
Related articles
Eli Lilly says experimental obesity drug combo shows stronger weight loss in trial
The drugmaker plans to begin Phase 3 trials combining its amylin drug eloralintide with tirzepatide by the end of the year after positive mid-stage results.
Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
Western biopharma companies are increasingly sourcing innovation from China as a wave of patent expirations approaches.
Wall Street Closes Out Strong Quarter as Investors Weigh Lilly's Mixed Obesity Drug Data
Stocks wrapped up a strong quarter even as new trial data on Eli Lilly's obesity treatment delivered a mixed picture for investors.
Health insurance premiums may jump sharply in 2027, experts warn
Many consumers are likely to face an increase of about 10% or more in their health insurance premiums in 2027, according to industry experts.
Alison Hammond has heart check-up after leaving This Morning midway through broadcast
The TV presenter said she is 'fine' but is undergoing a heart check-up after leaving the set of This Morning partway through Friday's show.
Kenyan runner Naomi Korir cut back training due to fistula-related leaks
The Commonwealth Games finalist says a congenital condition forced her to scale back running even as she kept competing at an elite level.